

18

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	09/689,136
		Filing Date	October 12, 2000
		First Named Inventor	Engelhardt, John
		Group Art Unit	1641
		Examiner Name	Sullivan, Daniel
Sheet 1 of 6		Attorney Docket No: 875.032US1	

JUN 02 2003
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE
TECH CENTER 1600/2003

RECEIVED

US PATENT DOCUMENTS						
Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
already of record (#10)	US-5,604,090	02/18/1997	Alexander, Ian E., et al.	435	5	06/06/1994
DS	US-5,691,176	11/25/1997	Lebkowski, J. S., et al.	435	172.3	06/02/1995
DS	US-5,834,182	11/10/1998	Alexander, Ian E., et al.	435	5	02/25/1997
DS	US-6,083,702	07/04/2000	Mitchell, L. G., et al.	435	6	08/13/1998
DS	US-6,200,560	03/13/2001	Couto, L. B., et al.	424	93.2	12/22/1999

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
DS	WO-94/13788 ✓	12/04/1992	Coruzzi, Laura A., et al.	C12N	7/01	
DS	WO-95/07351 ✓	09/10/1993	Jarrell, Kevin A.	C12N	15/10	
DS	WO-97/22250 ✓	12/13/1996	Mitchell, Lloyd G.	A01N	43/04	
DS	WO-98/09657 ✓	09/06/1996	Wilson, James M., et al.	A61K	48/00	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DS		"(S)-(+)-Camptothecin; 4-Ethyl-4-hydroxy-1H-pyrano[3', 4': 6,7] indolizino [1,2-b] quinoline-3, 14 (4H, 12H) dione", <u>Calbiochem</u> , Camptothecin, Camptotheca acuminata,(October 2, 2000),1-2
DS		"Adriamycin; 14-Hydroxydaunomycin, HCl", <u>Calbiochem</u> , Doxorubicin, Hydrochloride, Catalog Number 324380,(October 21, 1998),1-2
DS		"Aminoglycoside antibiotic. Inhibits myeloperoxidase-dependent oxidant cell injury", <u>Calbiochem</u> , Tobramycin, Free Base, Catalog Number 614005,(August 26, 1999),1
DS		"Cancer Research", Contribution to Society, http://www.bikaken.or.jp/mcrf/e/contributiiion , (December 4, 2000),2 pages
DS		"Carbobenzoxy-L-leucyl-L-leucinal", <u>Calbiochem</u> , MG-132, Catalog Number 474790,(October 15, 1999),1-2
DS		"Drugs for Selection of Genetic Markers Reagents for positive and negative selection of Genes involved in Nucleotide Metabolism", <u>Calbiochem</u> , (March 2002),6 pages
DS		"EPA; 20:5 w-3; 5,8, 11, 14, 17-Eicosapentaenoic Acid", <u>Calbiochem</u> , Eicosapentaenoic Acid, Catalog Number 324875,(December 7, 1998),1-2
DS		"Epoxomicin- a potent and selective proteasome inhibitor", <u>Affiniti Research Products Limited</u> , 2 pages
DS		"LDP-341", <u>Millennium Pharmaceuticals</u> , http://www:biospace.com/ct/detail.cfm?ClinicalID=266404 ,1 page
DS		"Mevinolin; MK-803", <u>Calbiochem</u> , Lovastatin, Catalog Number 438185,(June 29, 2001),1-2

EXAMINER D. SullivanDATE CONSIDERED 7/25/03

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/689,136</td> </tr> <tr> <td>Filing Date</td> <td>October 12, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Engelhardt, John</td> </tr> <tr> <td>Group Art Unit</td> <td>1641</td> </tr> <tr> <td>Examiner Name</td> <td>Sullivan, Daniel</td> </tr> </table>		Application Number	09/689,136	Filing Date	October 12, 2000	First Named Inventor	Engelhardt, John	Group Art Unit	1641	Examiner Name	Sullivan, Daniel
Application Number	09/689,136												
Filing Date	October 12, 2000												
First Named Inventor	Engelhardt, John												
Group Art Unit	1641												
Examiner Name	Sullivan, Daniel												
Sheet 2 of 6		Attorney Docket No: 875.032US1											

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DS		"MK-733", <u>Calbiochem</u> , Simvastatin, Catalog Number 567020,(October 25, 2001),2	✓
DS		"Polymer Vectors Endosomal release and cytoplasmic delivery", <u>Endosomal Release</u> , http://web.bham.ac.uk/can4psd4/nonviral/endosome.html ,(June 3, 2001),1	✓
DS		"Product Data Sheet", <u>Moravek Biochemicals, Inc.</u> , M-1535, Ritonavir,(July 12, 2001),1 page	✓
DS		"Product Information", <u>Sigma</u> , Cyclosporin A, Sigma Product No. C3662,(October 28, 1996),3 pages	✓
DS		"Product Information", <u>Sigma</u> , Bleomycin Sulfate, Sigma Prod. No. B5507,(November 25, 1996),2 pages	✓
DS		"Proteasome Inhibitors", <u>Peptides International, Inc.</u> , (April 16, 2001),1-2	✓
DS		"Tannic Acid, A.C.S. reagent", <u>Sigma</u> , www.sigma-aldrich.com/sacatalog.nsf/productlookup/Aldrich403040?OpenDocument ,1 page	✓
DS		ADAMS, JULIAN , et al., "Novel Inhibitors of the Proteasome and Their Therapeutic Use in Inflammation", <u>Annual Reports in Medicinal Chemistry</u> , Academic Press, Inc.,(1996),279-288	✓
AC		ANDRE, PATRICE , et al., "An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses", <u>Proc. National Academy of Science USA</u> , vol. 95, (October 1998),13120-13124	✓
DS		BANERJEE, D. , et al., "The treatment of respiratory pseudomonas infection in cystic fibrosis: What drug and which way?", <u>Drugs</u> , 60(5), abstract,(November 2000),1 page	✓
DS		BIES, J. , et al., "Oncogenic activation of c-Myb by Carboxyl-Terminal truncation leads to Decreased Proteolysis by the Ubiquitin-26S proteasome pathway", <u>Oncogene</u> , vol. 14, no. 2, Abstract,(January 16, 1997),1 page	✓
DS		BOKKALA, SHAILA , et al., "Angiotensin II-induced Down-regulation of Inositol Trisphosphate Receptors in WB Rat Liver Epithelial Cells", <u>Journal of Biological Chemistry</u> , vol. 272, no. 19, (May 9, 1997),12454-12461	✓
DS		BONACORSI, STEPHANE , et al., "Comparative In Vitro Activities of Meropenem, Imipenem, Temocillin, Piperacillin, and Ceftazidime in Combination with Tobramycin, Rifampin, or Ciprofloxacin against Burkholderia cepacia Isolates from Patients with Cystic Fibrosis", <u>Antimicrobial Agents and Chemotherapy</u> , vol. 43, no. 2, (February 1999),213-217	✓
DS		BRAND, STEPHEN , et al., "Role of the Proteasome in Rat Indomethacin-Induced Gastropathy", <u>Gastroenterology</u> , vol. 116, no. 4, (1999),865-873	✓
DS		BRAVO, LAURA , "Polyphenols: Chemistry, Dietary Sources, Metabolism and Nutritional Significance", <u>Nutrition Reviews</u> , vol. 56, no. 11, (November 1998),317-333	✓
DS		BUGG, C. , et al., "SRI6975 Increases Adenovirus Mediated Gene Transfer Through the Apical Surface of Polarized MDCK Cell Monolayers", <u>Cystic Fibrosis</u>	✓

EXAMINER

DSullivan


DATE CONSIDERED

7/25/03

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1641
Examiner Name	Sullivan, Daniel

Sheet 3 of 6

Attorney Docket No: 875.032US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Foundation: 2000 North American CF Conference, (November 2000), 1	
DS		CANTIN, ANDRE M., et al., "Aerosolized Prolastin Suppresses Bacterial Proliferation in a Model of Chronic Pseudomonas aeruginosa Lung Infection", <i>American Journal of Respiratory and Critical Care Medicine</i> , vol. 160, (1999), 1130-1135	
DS		CHUNG, KING-THOM , et al., "Tannins and Human Health: A Review", <i>Critical Reviews in Food Science and Nutrition</i> , 38(6), (1998), 421-464	
DS		DESAI, SHYAMAL , et al., "Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin", <i>Journal of Biological Chemistry</i> , (September 26, 1997), 24159-24164	
(Already record #7)	#7	DUAN, DONGSHENG , et al., "Circular intermediates of recombinant adenovirus having defined structural characteristics responsible for long-term episomal persistence in muscle tissue", <i>J. of Virology</i> , 72 (11), (Nov. 1998), pp. 8568-8577	
DS		FAYADAT, LAURENCE , et al., "Degradation of Human Thyroperoxidase in the Endoplasmic Reticulum Involves Two Different Pathways Depending on the Folding State of the Protein", <i>Journal of Biological Chemistry</i> , vol. 275, no. 21, (May 26, 2000), 15948-15954	
DS		FENTEANY, GABRIEL , et al., "Lactacystin, Proteasome Function, and Cell Fate", <i>Journal of Biological Chemistry</i> , vol. 273, no. 15, (April 10, 1998), 8545-8548	
DS		FIGUEIREDO-PEREIRA, MARIA , et al., "The Antitumor Drug Aclacinomycin A, Which Inhibits the Degradation of Ubiquitinated Proteins, Shows Selectivity for the Chymotrypsin-like Activity of the Bovine Pituitary 20 S Proteasome", <i>Journal of Biological Chemistry</i> , (July 12, 1996), 16455-16459	
DS		GABIZON, ALBERTO , "Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals", <i>Advanced Drug Delivery Reviews</i> , (1997), 337-344	
DS		GABIZON, ALBERTO , et al., "Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes", <i>Journal of Liposome Research</i> , 3(3), (1993), 517-528	
DS		GARBER, KEN , "Taking Garbage In, Taking Cancer Out?", <i>Science</i> , vol. 295, (January 25, 2002), 612-613	
DS		HASEGAWA, S. , et al., "Microtubule involvement in the intracellular dynamics for gene transfection mediated by cationic liposomes", <i>Gene Therapy</i> , vol. 8, (2001), 1669-1673	
DS		HONG, J. , et al., "Identification of SRI6975, A Compound that Enhances Adenovirus-Mediated Gene Expression in Polarized Epithelial Cells", <i>Cystic Fibrosis Foundation: 2000 North American CF Conference</i> , (November 2000), 1-2	
DS		HSU, A. , et al., "Ritonavir. Clinical pharmacokinetics and interactions with other	

EXAMINER

DSullivan

DATE CONSIDERED

7/25/03


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/689,136
		Filing Date	October 12, 2000
		First Named Inventor	Engelhardt, John
		Group Art Unit	1641
		Examiner Name	Sullivan, Daniel
Sheet 4 of 6		Attorney Docket No: 875.032US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		anti-HIV agents", Clin Pharmacokinet, 35(6), abstract,(December 1998),1 page	
RS		HUANG, L. , et al., "Efficient lipofection with cisplatin-resistant human tumor cells", Cancer Gene Therapy, vol. 3, no. 2, (1996),107-112	✓
DS		IQBAL, MOHAMED , et al., "Potent Inhibitors of Proteasome", Journal of Medicinal Chemistry, vol. 38, no. 13, (1995),2276-2277	✓
RF		KIM, KYUNG BO , et al., "Proteasome Inhibition by the Natural Products Epoxomicin and Dihydroeponemycin: Insights into Specificity and Potency", Bioorganic & Medicinal Chemistry Letters, (1999),3335-3340	✓
RF		LEE, SANG GOO , et al., "Enhancement of adenoviral transduction with polycationic liposomes in vivo", Cancer Gene Therapy, vol. 7, no. 10, (2000),1329-1335	✓
RS		LEE, D. H., "Proteasome Inhibitors: Valuable New Tools For Cell Biologists", Trends in Cell Biology, 8, (October 1998),pp. 397-403	✓
RS		LEE, DO HEE , et al., "Selective Inhibitors of the Proteasome-dependent and Vacuolar Pathways of Protein Degradation in Saccharomyces cerevisiae", Journal of Biological Chemistry, (November 1, 1996),27280-27284	✓
RF		LEE, DO HEE , et al., "The Proteasome Inhibitors and Their Uses", Proteasomes: The World of Regulatory Proteolysis, (2000),154-175	✓
RS		LU, WEI , et al., "HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism", Blood, vol. 96, no. 1, (July 1, 2000),250-258	✓
RS		LUO, HONGYU , et al., "A Proteasome Inhibitor Effectively Prevents Mouse Heart Allograft Rejection", Transplantation, vol. 72, no. 2, (July 27, 2001),196-202	✓
RF		MASTROIANNI, CLAUDIO M., et al., "Ex Vivo and In Vitro Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Apoptosis", Journal of Infectious Diseases (182), (November 2000),1536-1539	✓
RF		MENG, LIHAO , et al., "Eponemycin Exerts Its Antitumor Effect through the Inhibition of Proteasome Function", Cancer Research, vol. 59, (June 15, 1999),2798-2801	✓
RF		MENG, LIHAO , et al., "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity", Proc. National Academy of Science USA, (August 1999),10403-10408	✓
RF		MEYER, STEPHANIE , et al., "Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF- κ B activation", Federation of European Biochemical Societies, (1997),354-358	✓
RF		MOSNAIM, ARON , et al., "Degradation Kinetics of Leucine5-Enkephalin by Plasma Samples from Healthy Controls and Various Patient Populations: In Vitro Drug Effects", American Journal of Therapeutics, vol. 7, (2000),185-194	✓
RS		NAM, SANGKIL , et al., "Tannic Acid Potently Inhibits Tumor Cell Proteasome Activity, Increases p27 and Bax Expression, and Induces G1 Arrest and	✓

EXAMINER 

DATE CONSIDERED

7/25/03

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	09/689,136
		Filing Date	October 12, 2000
		First Named Inventor	Engelhardt, John
		Group Art Unit	1641
		Examiner Name	Sullivan, Daniel
Sheet 5 of 6		Attorney Docket No: 875.032US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Apoptosis", <u>Cancer Epidemiology, Biomarkers & Prevention</u> , vol. 10, (October 2001),1083-1088	
DS		NEPKA, CHARITINI , et al., "Chemopreventive activity of very low dose dietary tannic acid administration in hepatoma bearing C3H male mice", <u>Cancer Letters</u> , vol. 141, (1999),57-62	
DS		NEPKA, CH. , et al., "Tannins, xenobiotic metabolism and cancer chemo-prevention in experimental animals", <u>European Journal of Drug Metabolism and Pharmacokinetics</u> , vol. 24, no. 2, (1999),183-189	
DS		PALOMBELLA, VITO , et al., "Role of the proteasome and NF-kB in streptococcal cell wall-induced polyarthritis", <u>Proc. National Academy of Science USA</u> , vol. 95, (December 1998),15671-15676	
DS		PETROV, VICTOR , et al., "Effect of Protease Inhibitors on Angiotensin-Converting Enzyme Activity in Human T-Lymphocytes", <u>American Journal of Hypertension</u> , vol. 13, no. 5, (May 2000),535-539	
DS		RAO, SHARMILA , et al., "Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase", <u>Proc. National Academy of Science USA</u> , vol. 96, (July 1999),7797-7802	
DS		SCHWARTZ, DONALD , et al., "The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance", <u>Proc. National Academy of Science USA</u> , vol. 96, (April 1999),4680-4685	
DS		SCHWARZ, KATRIN , et al., "The Selective Proteasome Inhibitors Lactacystin and Epoxomicin can be used to either Up- or Down-Regulate Antigen Presentation at Nontoxic Doses", <u>Journal of Immunology</u> , (2000),6147-6157	
DS		SHAH, SHIMUL , et al., "26S Proteasome Inhibition Induces Apoptosis and Limits Growth of Human Pancreatic Cancer", <u>Journal of Cellular Biochemistry</u> , vol. 82, (2001),110-122	
DS		SMITH, H. , et al., "Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid", <u>Cancer Res.</u> , 59(21), abstract,(November 1999),1 page	
DS		SON, KYONGHEE , et al., "Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer", <u>Proc. National Academy of Science USA</u> , vol. 91, (December 1994),12669-12672	
DS		SON, K , et al., "Factors influencing the drug sensitization of human tumor cells for in situ lipofection", <u>Gene Therapy</u> (3), (1996),630-634	
DS		SON, KYONGHEE , et al., "Nitric oxide-mediated tumor cell killing of cisplatin-based interferon- γ gene therapy in murine ovarian carcinoma", <u>Cancer Gene Therapy</u> , vol. 7, no. 10, (2000),1324-1328	
DS		TEODORI, L. , et al., "Reduction of 1-beta-D-arabinofuranosylcytosine and adriamycin cytotoxicity following cell cycle arrest by anguidine", <u>Cancer Res.</u> , 41(4), abstract,(April 1981),1 page	
DS		TWEEDALE, TONY , "[Dioxin-I] Inhibits Estrogen-Induced Breast Cancer Cell	

EXAMINER

D. Sullivan

DATE CONSIDERED *1/25/03*

Substitute for form 1449A/PTO													
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/689,136</td> </tr> <tr> <td>Filing Date</td> <td>October 12, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Engelhardt, John</td> </tr> <tr> <td>Group Art Unit</td> <td>1641</td> </tr> <tr> <td>Examiner Name</td> <td>Sullivan, Daniel</td> </tr> </table>		Application Number	09/689,136	Filing Date	October 12, 2000	First Named Inventor	Engelhardt, John	Group Art Unit	1641	Examiner Name	Sullivan, Daniel
Application Number	09/689,136												
Filing Date	October 12, 2000												
First Named Inventor	Engelhardt, John												
Group Art Unit	1641												
Examiner Name	Sullivan, Daniel												
Sheet 6 of 6		Attorney Docket No: 875.032US1											

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL		Proliferation", Reuters Health, http://lists.essential.org/pipermail/dioxin-l/Week-of-Mon-2000103/000096.html , (December 1999), 1 page	
PL		WOESSNER, RICHARD , et al., "Comparison of Three Approaches to Doxorubicin Therapy: Free Doxorubicin; Liposomal Doxorubicin, and B-Glucuronidase-Activated Prodrug (HMR 1826)", <u>Anticancer Research</u> , (2000),2289-2296	✓
DP		WOJCIK, CEZARY , et al., "Lovastatin and simvastatin are modulators of the proteasome", <u>International Journal of Biochemistry & Cell Biology</u> , (32), (2000),957-965	✓
DS		WORKING, PETER , et al., "Pharmacological-Toxicological Expert Report (Stealth Liposomal Doxorubicin HCl)", <u>Human & Experimental Toxicology</u> , (1996),752-785	✓

EXAMINER

D.Sullivan

DATE CONSIDERED

7/25/03